Jinxin Fertility Group Limited
錦欣生殖醫療集團有限公司*
(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 1951)

POSITIVE PROFIT ALERT

The announcement is made by Jinxin Fertility Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders (the "**Shareholders**") and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards) for the year ended December 31, 2019, it is expected that the net profit of the Group for the year ended December 31, 2019 will increase by over 90% compared to that of the Group for the year ended December 31, 2018. Such increase was primarily attributable to (i) the acquisition of the United States operations by the Group in December 2018; and (ii) the increase in IVF (in vitro fertilization) treatment cycles and profit margin of the Group.

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2019. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2019, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit and risk management committee of the Board. Shareholders and potential investors of the Company should refer to the annual results announcement of the Group for the year ended December 31, 2019, which is expected to be published by the end of March 2020.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Wang Bin
Chairman

Hong Kong, March 17, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Zhong Ying, Ms. Yan Xiaoqing and Dr. John G. Wilcox, as executive Directors; Mr. Wang Bin, Mr. Fang Min, Ms. Hu Zhe and Mr. Dong Yang, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Lim Haw Kuang, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *For identification purpose only*